Drug search by name

Zelboraf and Cutaneous malignancies

Result of checking the interaction of drug Zelboraf and disease Cutaneous malignancies for safety when used together.

Check result:

Zelboraf <> Cutaneous malignancies

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Cutaneous squamous cell carcinoma, keratoacanthoma, and melanoma occurred at a higher incidence in patients receiving vemurafenib. Potential risk factors associated included age (> 65 years), prior skin cancer, and chronic sun exposure. It is recommended to perform dermatologic evaluations prior to initiation of therapy and periodically thereafter as clinically indicated. Consider dermatologic monitoring for 6 months following discontinuation of vemurafenib.

Zelboraf

Generic Name: vemurafenib

Brand Name: Zelboraf

Synonyms: n.a.

What is Zelboraf?